Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Animals
Cannabidiol
/ pharmacology
Dopaminergic Neurons
/ drug effects
Dronabinol
/ pharmacology
Hippocampus
/ drug effects
MAP Kinase Signaling System
/ drug effects
Male
Memory
/ drug effects
Phosphorylation
Psychotropic Drugs
/ pharmacology
Rats, Sprague-Dawley
Reward
Ventral Tegmental Area
/ drug effects
cannabidiol
delta-9-tetrahydrocannabinol
dopamine
extracellular signal-regulated kinase
ventral hippocampus
ventral tegmental area
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
ISSN: 1529-2401
Titre abrégé: J Neurosci
Pays: United States
ID NLM: 8102140
Informations de publication
Date de publication:
30 10 2019
30 10 2019
Historique:
received:
28
03
2019
revised:
16
08
2019
accepted:
03
09
2019
pubmed:
2
10
2019
medline:
1
7
2020
entrez:
2
10
2019
Statut:
ppublish
Résumé
Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using
Identifiants
pubmed: 31570536
pii: JNEUROSCI.0708-19.2019
doi: 10.1523/JNEUROSCI.0708-19.2019
pmc: PMC6820200
doi:
Substances chimiques
Psychotropic Drugs
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8762-8777Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2019 the authors.
Références
Arch Gen Psychiatry. 2012 Jan;69(1):27-36
pubmed: 22213786
J Neurosci. 2003 Mar 15;23(6):2371-82
pubmed: 12657697
Br J Pharmacol. 2017 Oct;174(19):3242-3256
pubmed: 28268256
J Neurosci. 2001 Jul 1;21(13):4915-22
pubmed: 11425919
Mol Psychiatry. 2019 Feb 15;:null
pubmed: 30770892
Elife. 2018 Oct 30;7:
pubmed: 30375971
J Neural Transm (Vienna). 2004 Dec;111(12):1583-92
pubmed: 15565492
Neuropsychopharmacology. 2010 Aug;35(9):1962-72
pubmed: 20463657
J Neurosci Res. 2008 Mar;86(4):776-84
pubmed: 17941053
Cannabis Cannabinoid Res. 2018 Nov 30;3(1):228-241
pubmed: 30515459
Arch Gen Psychiatry. 2005 Apr;62(4):379-86
pubmed: 15809405
PLoS One. 2013 Oct 21;8(10):e76918
pubmed: 24204703
J Neurosci. 1998 Dec 1;18(23):10037-44
pubmed: 9822758
Neuropsychopharmacology. 2015 May;40(6):1343-52
pubmed: 25249057
Cannabis Cannabinoid Res. 2018 Apr 01;3(1):94-107
pubmed: 29682609
Neuropsychopharmacology. 2011 Mar;36(4):827-36
pubmed: 21150914
J Neurosci. 2013 Sep 11;33(37):14693-704
pubmed: 24027270
PLoS One. 2013 Aug 16;8(8):e72006
pubmed: 23977192
Neurobiol Aging. 2004 Jul;25(6):795-806
pubmed: 15165704
Eur J Pharmacol. 2005 Apr 11;512(2-3):199-205
pubmed: 15840405
Int J Neuropsychopharmacol. 2013 Jul;16(6):1407-19
pubmed: 23298518
Neuropsychopharmacology. 2016 Nov;41(12):2839-2850
pubmed: 27296152
Learn Mem. 2009 Mar 24;16(4):273-8
pubmed: 19318469
J Neurosci. 2006 Jun 14;26(24):6458-68
pubmed: 16775133
J Neurosci. 2011 Aug 3;31(31):11172-83
pubmed: 21813678
Br J Pharmacol. 2018 Jun;175(11):2097-2115
pubmed: 29574880
Learn Mem. 2003 Jan-Feb;10(1):26-39
pubmed: 12551961
Biol Psychiatry. 2016 Aug 1;80(3):216-25
pubmed: 26681496
J Psychopharmacol. 2006 Sep;20(5):683-6
pubmed: 16401651
Mol Psychiatry. 2003 Jan;8(1):50-9, 9
pubmed: 12556908
J Psychopharmacol. 2013 Jan;27(1):19-27
pubmed: 23042808
Neuropsychopharmacology. 2015 May;40(6):1436-47
pubmed: 25510937
J Physiol. 2006 Dec 15;577(Pt 3):907-24
pubmed: 16959856
Transl Psychiatry. 2016 Feb 16;6:e738
pubmed: 26882038
Am J Psychiatry. 2003 Dec;160(12):2190-7
pubmed: 14638589
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Br J Pharmacol. 2007 Nov;152(5):583-93
pubmed: 17641667
Lancet. 1998 Aug 22;352(9128):620-1
pubmed: 9746027
Sci Rep. 2017 Sep 12;7(1):11420
pubmed: 28900286
Neuropsychopharmacology. 2010 Feb;35(3):764-74
pubmed: 19924114
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10164-9
pubmed: 17553960
Mol Oncol. 2015 Apr;9(4):906-19
pubmed: 25660577
J Affect Disord. 2010 Jul;124(1-2):164-9
pubmed: 19913919
Cereb Cortex. 2017 Feb 1;27(2):1297-1310
pubmed: 26733534
J Neurosci. 2016 May 4;36(18):5160-9
pubmed: 27147666
Neuropsychopharmacology. 2012 Nov;37(12):2624-34
pubmed: 22850737
Neuroscience. 2005;136(3):811-22
pubmed: 16344153
Annu Rev Neurosci. 2012;35:203-25
pubmed: 22443509
Neuroscience. 1983 Oct;10(2):301-15
pubmed: 6633863
J Neurosci. 2009 Nov 25;29(47):14764-9
pubmed: 19940171
J Neurosci. 2000 Feb 15;20(4):1635-42
pubmed: 10662853
Front Behav Neurosci. 2014 Jan 29;8:18
pubmed: 24523683
Life Sci. 2005 Feb 4;76(12):1307-24
pubmed: 15670612
Neuropharmacology. 2010 Jul-Aug;59(1-2):121-7
pubmed: 20417220
J Physiol. 2006 May 1;572(Pt 3):789-98
pubmed: 16513670
Neuropharmacology. 2006 Apr;50(5):621-31
pubmed: 16386766
Curr Pharm Des. 2012;18(32):4966-79
pubmed: 22716148
Cannabis Cannabinoid Res. 2017 Jan 01;2(1):8-20
pubmed: 28861501
Eur J Neurosci. 2018 Jun;47(11):1385-1400
pubmed: 29776015
Bioorg Med Chem Lett. 1998 Oct 20;8(20):2839-44
pubmed: 9873633
Eur J Neurosci. 1999 Dec;11(12):4213-25
pubmed: 10594647
Brain Struct Funct. 2015 Mar;220(2):919-40
pubmed: 24407853
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1867-72
pubmed: 10677548
Schizophr Bull. 2012 Sep;38(5):950-7
pubmed: 22355184
J Clin Neurophysiol. 1992 Jul;9(3):441-8
pubmed: 1517412
Int J Neuropsychopharmacol. 2014 Oct 31;18(5):null
pubmed: 25618402
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Cell Adh Migr. 2008 Jul-Sep;2(3):202-7
pubmed: 19262113
Br J Pharmacol. 2001 Oct;134(4):845-52
pubmed: 11606325
Chem Phys Lipids. 2002 Dec 31;121(1-2):73-82
pubmed: 12505692
Transl Psychiatry. 2012 Mar 20;2:e94
pubmed: 22832859
Epilepsia. 2014 Jun;55(6):791-802
pubmed: 24854329
Neuron. 2013 Aug 21;79(4):814-28
pubmed: 23972602
Schizophr Res. 2011 Aug;130(1-3):216-21
pubmed: 21592732
Mol Psychiatry. 2014 May;19(5):536-43
pubmed: 24589887